Swiss laboratory NOVARTIS is going to acquire 51% of the capital in the US company, IDENIX, which specialises in the development of hepatitis B treatment and anti-virals. NOVARTIS will pay USD 225 million in cash and more than USD one hundred million during the development of the new medicines by the company to obtain its stake.